From NIH Staff (A2CPS):
I am contacting you on behalf of the NIH for the launch of a NIH Common Fund program: Acute to Chronic Pain Signatures. We are reaching out to those with possible interest in the series of funding opportunities that we have recently released. If you would be willing to distribute information about these opportunities to your community, we would appreciate it.
The Common Fund’s Acute to Chronic Pain Signatures program seeks to identify candidate biomarkers and combine them into biosignatures predictive of the susceptibility or resilience to the development of chronic pain. Ultimately, the program aims to develop a database of pain-related biomarkers that can inform subsequent pain research. These biomarkers will accelerate therapy development and guide pain prevention strategies.
Five opportunities for this program are now available:
• Multisite Clinical Center Common Fund Acute to Chronic Pain Signatures Program: Acute Peri-operative Pain (UM1) Clinical Trials Optional
• Multisite Clinical Center Common Fund Acute to Chronic Pain Signatures Program: Acute Pain from Musculoskeletal Trauma (UM1) Clinical Trials Optional
• Clinical Coordination Center for Common Fund Acute to Chronic Pain Signatures (A2CPS) Program (U24) Clinical Trials Optional
• Omics Data Generation Centers (ODGCs) for Common Fund Acute to Chronic Pain Signatures Program (U54) Clinical Trial Optional
• Data Integration and Resource Center (DIRC) for Common Fund Acute to Chronic Pain Signatures Program (U54) Clinical Trial Optional
For those who are interested, letters of intent are due September 24, 2018 and applications are due October 24, 2018. An informational webinar will be held on September 6th, 2018 from 2-4 PM, EST.
Join us via WebEx using this link:
Call-in toll number (US/Canada): 1-650-479-3208
Event number: 624 155 354
Event password: PainSig
For additional information, please visit https://commonfund.nih.gov/pain, or contact
Linda L. Porter, Ph.D. (RFA-RM-18-033, RFA-RM-18-034, RFA-RM-18-035)
National Institute on Neurological Disorders and Stroke (NINDS)
John Satterlee, Ph.D. (RFA-RM-18-031, RFA-RM-18-032)
National Institute on Drug Abuse (NIDA)